固定用量配合剤を用いた心血管疾患予防のための医薬品のカーボンフットプリント改善
Improving the carbon footprint of medications for cardiovascular disease prevention using fixed dose combinations (原題)
C Kennedy, M Kavanagh, A Saleh, D R Grimes, M Hennessy, F Moriarty
🤖 gxceed AI 要約
日本語
アイルランドの高齢者コホート(TILDA)を用い、高血圧治療における固定用量配合剤(FDC)の利用率ギャップを推計。FDC普及により服薬アドヒアランス改善と入院減少を通じ、人口100万人あたり年17.82ktCO2eqの削減が可能と試算した。心血管疾患予防におけるFDCの環境影響を初めて定量化した研究である。
English
Using the Irish TILDA cohort, the authors estimate the underuse of fixed dose combination (FDC) antihypertensives among adults over 50. Full FDC adoption could cut emissions by ~17.82 ktCO2eq per million people annually, combining lower medication footprint and fewer CVD hospital admissions. This is the first estimate of FDC environmental impact in CVD prevention.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
医療セクターの脱炭素はScope 3排出・サプライチェーン開示の観点で日本企業にも関連するが、本論文は処方実務寄りでSSBJ・有報対応への直接的示唆は限定的。
In the global GX context
Adds a healthcare-sector decarbonization data point relevant to Scope 3 and supply-chain emissions accounting, though it sits outside core TCFD/ISSB disclosure frameworks and speaks mainly to clinical prescribing practice.
👥 読者別の含意
🔬研究者:医療介入の炭素フットプリントを定量化する手法の一事例として参照できる。
🏢実務担当者:医療・ヘルスケア関連企業がScope 3上流の医薬品排出を評価する際の参考になる。
🏛政策担当者:処方政策と脱炭素政策の接点を示すが、規制枠組みへの直接的含意は小さい。
📄 Abstract（原文）
Abstract Background Healthcare systems are responsible for 4%–5% of the emissions of greenhouse gases worldwide. Fixed dose combination (FDC) medications have demonstrated benefits for patients with CVD including improved adherence, a reduction in CV outcomes and greater cost-effectiveness.[1] However, they remain underutilised. The carbon footprint of FDCs compared to single drug preparations has not been evaluated and may indicate an additional benefit. Purpose To estimate the change in carbon footprint due to increased anti-hypertensive FDC utilisation. Methods The utilisation gap for FDCs amongst patients over 50 years old with hypertension prescribed two or more anti-hypertensive medications was determined from the Irish Longitudinal Study on Ageing (TILDA). The carbon footprint for a standard daily dose of an anti-hypertensive medication, the reduction in CVD related hospital admissions due to anti-hypertensive FDC use as well as the carbon footprint of an average hospital admission have been estimated previously.[1-3] With this information, the reduction in CO2 emissions for a population of one million was estimated. Results For the TILDA cohort, the utilisation gap for anti-hypertensive FDCs was 201,062 individuals per million. The annual carbon footprint of one anti-hypertensive medication was 7.97 kgCO2eq. With the widespread and complete adoption of FDCs, the reduction in emissions was estimated at 1.60 kiloton(kt) CO2eq per million. The reduction in annual hospital admissions and the subsequent reduction in emissions was estimated to be 16.23 ktCO2eq. The total reduction in carbon footprint of FDCs for hypertension was 17.82 ktCO2eq annually. This is comparable to the carbon footprint for 250 transatlantic flights, and a similar reduction is achievable by switching 700,000 incandescent bulbs to LEDs. Conclusions This is the first estimation of the environmental impact of FDCs in the setting of CVD prevention. Further modelling to determine the precision and uncertainty of these estimates will be performed as well as the potential carbon footprint reductions for other FDC medication groups and on a global scale. These findings may impact prescribing practice for CVD prevention and influence patient preference.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.1093/eurheartj/ehag785.3513first seen 2026-10-28 05:00:37 · last seen 2026-10-31 05:06:10
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。